Equillium Inc (EQ) Gagner

Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.